Kymriah has been listed, hope of cure

Korea Leukemia Patient Organization said, "The Yoon Seok-yeol government should also introduce a rapid registration system"

Patients immediately welcomed the confirmation of health insurance benefits of the acute lymphocytic leukemia and lymphoma CAR-T treatment Kymriah (Tisagencleucel).

 

The patients urged the transition committee of the next presidential post and Yoon Seok-yeol to quickly register new drugs directly related to life as health insurance benefits.

 

On the 31st, Korea Leukemia patient organization said, "The cost of one-time non-reimbursement payment is 460 million won, and the ultra-high-priced Kymriah passed the Health Policy Review Committee and acquired health insurance benefits to even hope for cure." Kymriah will be listed with an upper limit of 360 million won for one-time health insurance from the 1st.

 

The Korea Leuchemia patient organization believes that the appeal of Cha Eun-chan's mother, Lee Bo-yeon, who left for heaven while preparing for Kymriah treatment, and the consent of tens of thousands of Cheongwadae petitioners influenced Kymriah's health insurance registration in a year and a month.

 

The National Human Rights Commission of Korea expressed its opinion to the MOHW to establish a rapid registration system for Kymriah's health insurance system, which was raised by the Korea Leukemia patient organization, also positively affected benefits.

 

The Korea Association of Patients urged the government to manage the risk sharing based on patient-level performance-based risk sharing that applies only to lymphoma, as well as Refund risk sharing and Extended Cap risk sharing, which are conditions for health insurance registration for Kymriah.

 

The Association of Patients argued, "The next presidential transition committee and the Yoon Seok-yeol government should also introduce a rapid registration system for new drugs that show excellent effects without alternative drugs for life-threatening patients such as Kymriah."